This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes

This study has been completed.
Information provided by:
Teva Pharmaceutical Industries Identifier:
First received: January 4, 2006
Last updated: June 29, 2012
Last verified: July 2009
This is a randomized, double-blind study to compare the efficacy and safety of daily doses of Cenestin 0.3 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women.

Condition Intervention Phase
Hot Flashes Drug: Cenestin 0.3 mg Tablets Other: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Double-blind, Placebo-controlled Trial to Demonstrate the Safety and Efficacy of Daily 0.3 mg Synthetic Conjugated Estrogens, A (Cenestin) for the Treatment of Vasomotor Symptoms in Postmenopausal Women

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Mean change in average frequency of moderate to severe hot flashes [ Time Frame: Baseline to Day 28 and to Day 84 ]
  • Mean change in severity of moderate to severe hot flashes [ Time Frame: Baseline to Day 28 and to Day 84 ]

Secondary Outcome Measures:
  • Safety and tolerability of Cenestin 0.3mg [ Time Frame: Throughout study ]

Estimated Enrollment: 400
Study Start Date: December 2005
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Cenestin 0.3 mg Tablets
1 tablet daily
Other Name: Synthetic conjugated estrogens, A
Placebo Comparator: 2 Other: Placebo
1 tablet daily
Other Name: Placebo tablets

Detailed Description:
The overall study duration will be approximately 16 weeks. After a screening/baseline period of up to 4 weeks patients will be randomized to receive either placebo tablets or Cenestin 0.3mg tablets

Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Naturally or surgically postmenopausal
  • At least 12 months since last menses or 6 weeks past surgery
  • Minimum of 7 daily or 50 weekly moderate to severe hot flashes

Exclusion Criteria:

  • Any contraindication to natural or synthetic estrogens
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00272935

  Show 49 Study Locations
Sponsors and Collaborators
Duramed Research
Study Chair: Duramed Research Protocol Chair Duramed Research, Inc
  More Information

Responsible Party: Duramed Protocol Chair, Duramed Research, Inc. Identifier: NCT00272935     History of Changes
Other Study ID Numbers: BR-CEN-301
Study First Received: January 4, 2006
Last Updated: June 29, 2012

Keywords provided by Teva Pharmaceutical Industries:
vasomotor symptoms

Additional relevant MeSH terms:
Hot Flashes
Signs and Symptoms
Estrogens, Conjugated (USP)
Estrogens, conjugated synthetic A
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 21, 2017